Restoring vision - Optogenetic gene therapy targeted at human ON-bipolar cells
Live date was Mar 25th, 2021
Missed the live date? Don't worry!
Scroll down to watch the event.
Optogenetic gene therapy holds promise to restore high-quality vision in blind patients. Although the ON-bipolar cells, the first retinal interneurons, make the most attractive targets for optogenetic vision restoration, they have remained inaccessible to human gene therapy due to the lack of a robust cell-specific promoter. We describe the design and functional evaluation of 770En_454P(hGRM6), a human GRM6 gene-derived, short promoter that drives strong and highly specific expression in both the rod- and cone-type ON-bipolar cells of the human retina. Expression also in cone-type ON-bipolar cells is of importance, since the cone-dominated macula mediates high-acuity vision and is the primary target of gene therapies. 770En_454P(hGRM6)-driven middle-wave opsin expression in ON-bipolar cells achieved lasting restoration of high visual acuity in the rd1 mouse model of late retinal degeneration. The new promoter enables precise manipulation of the inner retinal network and paves the way for clinical application of gene therapies for high-resolution optogenetic vision restoration, raising hopes of significantly improving the life quality of people suffering from blindness.
- Next-generation retinal gene therapy with AAV
- Promoter design and evaluation
- Human post-mortem retinal explant culturing
- Concept of ON-bipolar cell-targeted gene therapies
- Procedure of designing a cell-type specific promoter
- Procedure of testing promoters in post-mortem retinal explant cultures
- Importance of the use of adequate experimental models
Empowering Retinal Gene Therapy with a Specific Promoter for Human Rod and Cone ON-Bipolar Cells. Hulliger EC, Hostettler SM, Kleinlogel S.
Mol Ther Methods Clin Dev. 2020 Mar 13;17:505-519.
Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances. McClements ME, Staurenghi F, MacLaren RE, Cehajic-Kapetanovic J.
Front Neurosci. 2020 Nov 11;14:570909.
Restoring vision. Roska B, Sahel JA.
Nature. 2018 May;557(7705):359-367.
About the speaker
Dr. Elmar Hulliger
Institute of Physiology, University of Bern
Elmar Hulliger, born in Switzerland, attained his master’s degree in Biotechnology from the ETH Zürich. Interested in applied research he subsequently joined Prof Dr. Sonja Kleinlogels Lab of Translational Optogenetics at the University of Bern for his PhD. There he established a translational model of post-mortem human retinal explant culturing and designed and evaluated synthetic promoters intended for optogenetic gene therapy. After graduating he continued his research in molecular biology and directed a pre-clinical trial of a next-generation optogenetic gene therapy.
Watch the Journal Club here
Other Journal Clubs and Webinars
Journal Club: Assessing Neuroinflammation-related Neural Damage by Monitoring the Retinotectal System
Neuroinflammation amplifies neural damage caused by genetic disorders or aging. Groh et al show that neuroinflammation has deleterious consequences for the optic nerve, and disease progression can be monitored with the OptoDrum.
Journal Club: The role of Nogo-A in visual deficits induced by retinal injury.
Nogo-A, an inhibitor of neural growth, prevents regeneration after injury. Blocking of Nogo-A aides recovery, also in the visual system after retinal damage. Baya Mdzomba show with our OptoDrum that visual behavior benefits from Nogo-A neutralization after retinal damage typically found in diabetic retinopathy or glaucoma.
Webinar: Visual Acuity as a Relevant Phenotype in Mouse Models of Rare Disease
The Jackson Laboratory will introduce their Neurobehavior Phenotyping Core, in which they also do visual acuity measurements. They will present two examples where the OptoDrum has been used to characterizte vision in animal models for rare disease: The Charcot-Marie-Tooth-disease, and Multiple-Sulfatase-Deficiency.
Journal Club: Measuring Visual Acuity and Contrast Sensitivity by Optomotor Reflex in Rodents
Optogenetic gene therapy holds great promise for healing blindness. Hulliger et al have developed a new promoter that effectively targets human ON bipolar cells. This is an important step towards clinical applications of optogenetic gene therapy for restoring vision.